-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-2B694 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-2B694 in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-2B694 in Metastatic Pancreatic Cancer Drug Details: A-2B694 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-2B694 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-2B694 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-2B694 in Non-Small Cell Lung Cancer Drug Details: A-2B694 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-2B694 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-2B694 in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-2B694 in Malignant Mesothelioma Drug Details: A-2B694 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-2B694 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-2B694 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-2B694 in Metastatic Colorectal Cancer Drug Details: A-2B694 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-2B694 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-2B694 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-2B694 in Metastatic Ovarian Cancer Drug Details: A-2B694 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AD-216 in Hyperlipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-216 in Hyperlipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-216 in Hyperlipidemia Drug Details: AD-216 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AD-217 in Hyperlipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-217 in Hyperlipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-217 in Hyperlipidemia Drug Details: AD-217 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AD-218 in Mixed Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-218 in Mixed Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-218 in Mixed Dyslipidemia Drug Details: AD-218 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-4101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DF-4101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DF-4101 in Solid Tumor Drug Details: DF-4101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-4101 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DF-4101 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DF-4101 in Renal Cell Carcinoma Drug Details: DF-4101 is under...
Testimonial
Your Drugs database is great, you can find all the information you want such as sales forecasts, countries, diseases, dates, clinical trials, and patent expiration. We are using this information to research the leading competitive products in our current project. In addition, we analyze the profiles of the leading products and use this information to set the differentiation profile of our own products and clarify our positioning. In terms of business forecasts, we are able to provide more objective figures by using the Drug Forecast and Market Analysis report series. The analysis of product share by disease (series of Drug Forecast and Market Analysis reports) is used for business feasibility assessment.”
The ability to evaluate or provide information on PJs in R&D from both product and disease perspectives (it is difficult to find a database that can be used comprehensively for both), stands GlobalData out from other providers. The release of new functions such as Likelihood of approval (LoA) analysis, which was something I wanted but did not exist, shows that GlobalData have done a good job of researching the industry and developing services from the customer’s perspective which is another positive.
GlobalData’s COVID-19 Bulletin, which is sent out several times a week, provides the latest information on COVID-19 related vaccines and therapeutics and is used as background information.
“GlobalData provides extensive and comprehensive Pharma and Biotech data along with spectacular customer support. I use their drug, trial and company data on a daily basis to support our sales and marketing efforts.”
“As a global biopharma R&D strategy consultancy, we use the GlobalData Pharma Intelligence platform across a broad spectrum of topics, it provides all key data in one place”